Literature DB >> 12193753

Activation of APCs through CD40 or Toll-like receptor 9 overcomes tolerance and precipitates autoimmune disease.

Hiroshi T Ichikawa1, Lucas P Williams, Benjamin M Segal.   

Abstract

Some autoreactive T cells normally escape thymic selection and persist in the periphery. This is true of myelin-reactive CD4(+) T cells, the effectors of experimental autoimmune encephalomyelitis (EAE) in laboratory animals and the presumed mediators of multiple sclerosis in humans. Nonetheless, most individuals do not succumb to autoimmune disease. There is growing evidence that while peripheral APCs stimulate immune responses against foreign Ags in the setting of tissue destruction and "danger," they actually maintain tolerance against self Ags under steady state conditions. We hypothesized that tolerance against candidate autoantigens could be reversed by activation of APCs via CD40 or Toll-like receptor 9 signaling. Adult SJL mice injected i.p. with a peptide fragment of proteolipid protein (a candidate autoantigen in multiple sclerosis) emulsified in IFA fail to mount lymphoproliferative or cytokine responses and are protected from EAE upon subsequent challenge with the Ag combined with adjuvants. Here we report that tolerized proteolipid protein-specific lymph node cells regain the ability to divide, differentiate along a Th1 lineage, and transfer EAE when reactivated in the presence of agonistic Abs against CD40 or CpG oligonucleotides. The effects of both anti-CD40 and CpG oligonucleotides are dependent upon induction of IL-12. Our findings suggest two mechanisms to explain the well-documented association between infectious illnesses and flare-ups of multiple sclerosis. Microbial pathogens could 1) release molecules that bind Toll-like receptors, and/or 2) stimulate microbe-specific T cells to express CD40 ligand, thereby licensing APCs that bear both microbial and autoantigens to break tolerance.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12193753     DOI: 10.4049/jimmunol.169.5.2781

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  33 in total

1.  Co-administration of CD40 agonistic antibody and antigen fails to overcome the induction of oral tolerance.

Authors:  Yeonseok Chung; Dong-Hyeon Kim; Seung-Ho Lee; Chang-Yuil Kang
Journal:  Immunology       Date:  2004-01       Impact factor: 7.397

Review 2.  The potential of mesenchymal stromal cells as a novel cellular therapy for multiple sclerosis.

Authors:  Jeffery J Auletta; Amelia M Bartholomew; Richard T Maziarz; Robert J Deans; Robert H Miller; Hillard M Lazarus; Jeffrey A Cohen
Journal:  Immunotherapy       Date:  2012-05       Impact factor: 4.196

Review 3.  Dendritic cells, Fc{gamma} receptors, and Toll-like receptors: potential allies in the battle against rheumatoid arthritis.

Authors:  T R D J Radstake; A W T van Lieshout; P L C M van Riel; W B van den Berg; G J Adema
Journal:  Ann Rheum Dis       Date:  2005-05-05       Impact factor: 19.103

4.  Phagocytes containing a disease-promoting Toll-like receptor/Nod ligand are present in the brain during demyelinating disease in primates.

Authors:  Lizette Visser; Marie-José Melief; Debby van Riel; Marjan van Meurs; Ella A Sick; Seiichi Inamura; Jeffrey J Bajramovic; Sandra Amor; Rogier Q Hintzen; Leonie A Boven; Bert A 't Hart; Jon D Laman
Journal:  Am J Pathol       Date:  2006-11       Impact factor: 4.307

5.  Plasmacytoid dendritic cells in multiple sclerosis: chemokine and chemokine receptor modulation by interferon-beta.

Authors:  Latt Latt Aung; Patricia Fitzgerald-Bocarsly; Suhayl Dhib-Jalbut; Konstantin Balashov
Journal:  J Neuroimmunol       Date:  2010-09-14       Impact factor: 3.478

6.  TLR-Induced Murine Dendritic Cell (DC) Activation Requires DC-Intrinsic Complement.

Authors:  Joong-Hyuk Sheen; Michael G Strainic; Jinbo Liu; Weijia Zhang; Zhengzi Yi; M Edward Medof; Peter S Heeger
Journal:  J Immunol       Date:  2017-05-24       Impact factor: 5.422

Review 7.  Escaping from rejection.

Authors:  Raymond J Lynch; Jeffrey L Platt
Journal:  Transplantation       Date:  2009-12-15       Impact factor: 4.939

Review 8.  Plasmacytoid dendritic cells and immunotherapy in multiple sclerosis.

Authors:  Felipe von Glehn; Leonilda M Santos; Konstantin E Balashov
Journal:  Immunotherapy       Date:  2012-10       Impact factor: 4.196

9.  CpG-ODN-mediated TLR9 innate immune signalling and calcium dyshomeostasis converge on the NFκB inhibitory protein IκBβ to drive IL1α and IL1β expression.

Authors:  Robyn De Dios; Leanna Nguyen; Sankar Ghosh; Sarah McKenna; Clyde J Wright
Journal:  Immunology       Date:  2020-03-18       Impact factor: 7.397

10.  Activation of antigen-presenting cells by microbial products breaks self tolerance and induces autoimmune disease.

Authors:  Hanspeter Waldner; Mary Collins; Vijay K Kuchroo
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.